Edition:
United States

Profile: Alexion Pharmaceuticals Inc (ALXN.O)

ALXN.O on Nasdaq

140.51USD
2:10pm EDT
Change (% chg)

$-2.65 (-1.85%)
Prev Close
$143.16
Open
$143.40
Day's High
$144.67
Day's Low
$139.86
Volume
877,018
Avg. Vol
1,934,135
52-wk High
$149.34
52-wk Low
$96.18

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

Company Address

Alexion Pharmaceuticals Inc

100 College St
NEW HAVEN   CT   06510-3210
P: +1203.2722596
F: +1203.2718198

Company Web Links